CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals (AMEX: JAV) announced today that it recently completed accrual of subjects in the last of four planned Phase 1 human pharmacokinetic (PK) studies needed to support its intended filing of a New Drug Application (NDA) next year for its intranasal ketamine product candidate, PMI-150.
